MBX Biosciences (MBX) Change in Account Payables (2023 - 2026)
MBX Biosciences (MBX) reported Change in Account Payables of $4.0 million for Q1 2026, up 353.96% on a YoY basis from $874958.9 in Q1 2025, and up 561.32% sequentially from -$861000.0 in Q4 2025.
MBX Biosciences (MBX) Change in Account Payables (2023 - 2026) Analysis & Trends
MBX Biosciences (MBX) has 4 years of Change in Account Payables data on file, last reported at $4.0 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 353.96% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 million (up 63.05% YoY), and the FY2025 full-year result was -$2.5 million, down 162.54% from the prior year.
- Change in Account Payables improved to $4.0 million in Q1 2026, from -$861000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $4.0 million in Q1 2026 to a low of -$2.0 million in Q3 2025.
- A 4-year average of $513300.0 and a median of $526500.0 in 2024 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables slumped 429.96% in 2025 and surged 353.96% in 2026, its largest moves.
- Tracing MBX's Change in Account Payables over 4 years: stood at -$310000.0 in 2023, then soared by 308.06% to $645000.0 in 2024, then plunged by 233.49% to -$861000.0 in 2025, then soared by 561.32% to $4.0 million in 2026.
- Business Quant data shows MBX's Change in Account Payables at $4.0 million in Q1 2026, -$861000.0 in Q4 2025, and -$2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | MBX Biosciences | 2.96 Bn | 2.96 Bn | - | 3.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.97 Mn |
| Mar 31, 2026 | 3.97 Mn |
| Dec 31, 2025 | -861,000.00 |
| Dec 31, 2025 | -861,000.00 |
| Sep 30, 2025 | -2.04 Mn |
| Sep 30, 2025 | -2.04 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Mar 31, 2025 | -1.56 Mn |
| Mar 31, 2025 | -1.56 Mn |
| Dec 31, 2024 | 645,000.00 |
| Dec 31, 2024 | 645,000.00 |
| Sep 30, 2024 | 2.23 Mn |
| Sep 30, 2024 | 2.23 Mn |
| Jun 30, 2024 | 579,000.00 |
| Jun 30, 2024 | 579,000.00 |
| Mar 31, 2024 | 474,000.00 |
| Mar 31, 2024 | 474,000.00 |
| Dec 31, 2023 | -310,000.00 |
| Dec 31, 2023 | -310,000.00 |